Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Wettan Keeley M Cain is EVP Gen Counsel, Legal & Comp at Gilead Sciences. OQRO lists 16 transactions filed with the SEC under this name, the latest on Nov 10, 2026, each linked to the official Form 4.
EVP Gen Counsel, Legal & Comp
Disclosures on record
16
Companies involved
1
As of the latest filing on , Wettan Keeley M Cain reported holding 5,360 shares of Gilead Sciences (GILD), worth about $906K at the last close of $169 (Nov 18, 2026). In the last 12 months, Wettan Keeley M Cain sold $558K in 1 sale.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Gilead Sciences GILD | 5,360 | 5,360 direct | $169 | $906K | Nov 6, 2026 |
Is this Wettan Keeley M Cain’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Gilead SciencesGILD
16 disclosures · Mar 2026 – Nov 2026 · 1 sold
Nov 6, 2026Sold~$558Kdisclosed Nov 10
DetailsOfficial recordSep 10, 2026590disclosed Sep 11
DetailsOfficial recordSep 10, 2026590disclosed Sep 11
DetailsOfficial recordSep 10, 2026285disclosed Sep 11
DetailsOfficial recordAug 10, 20266,002disclosed Aug 11
DetailsOfficial recordAug 10, 20266,002disclosed Aug 11
DetailsOfficial recordAug 10, 20262,908disclosed Aug 11
DetailsOfficial recordJun 10, 2026589disclosed Jun 11
DetailsOfficial recordJun 10, 2026589disclosed Jun 11
DetailsOfficial recordJun 10, 2026283disclosed Jun 11
DetailsOfficial recordMar 10, 20265,050disclosed Mar 12
DetailsOfficial recordMar 10, 202619Kdisclosed Mar 12
DetailsOfficial recordMar 10, 20261,246disclosed Mar 12
DetailsOfficial recordMar 10, 20261,246disclosed Mar 12
DetailsOfficial recordMar 10, 2026606disclosed Mar 12
DetailsOfficial recordFeb 27, 2026470disclosed Mar 2
DetailsOfficial recordWettan Keeley M Cain has no open-market purchase on record since 2026. Sales in 1 of the 1 years since 2026.
Wettan Keeley M Cain reported 0 open-market purchases and 1 sale since 2026; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $558K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Nov 6, 2026, Wettan Keeley M Cain reported holding 5,360 shares of Gilead Sciences (GILD). At the last close of $169 on Nov 18, 2026, that is about $906K. This is the stake disclosed in filings, not a net worth.
No public filing gives Wettan Keeley M Cain's net worth. What SEC Form 4 shows is the stock stake: 5,360 shares of Gilead Sciences (GILD), about $906K at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
In SEC filings of the last 12 months, Wettan Keeley M Cain reported 1 open-market sale worth $558K, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Wettan Keeley M Cain has no open-market purchase on record since 2026. Sales in 1 of the 1 years since 2026.
In SEC filings since 2026: no open-market purchase is on record; the latest open-market sale is from 2026.
Gilead Sciences (GILD), from 2026 to 2026: 0 purchases and 1 sale.
Wettan Keeley M Cain reported 0 open-market purchases and 1 sale here, 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.